-
2023-503795-24-00
7
2022-09-16
Avanced Non-Small Cell Lung Cancer
-
2022-502425-18-00
5
2022-04-19
Adenocarcinoma of the prostate
-
2023-505261-84-00
5
2020-10-06
Primary high risk leiomyosarcoma or liposarcoma of retroperitoneal spa
-
2025-522301-37-00
4
2026-06-24
Nonsegmental vitiligo
-
2025-523474-16-00
7
2026-06-09
Malignancies with Documented KRAS, BRAF and Other Selected RAS/MAPK Mu
-
2025-521666-10-01
4
2026-06-08
Mantle Cell Lymphoma
-
2025-523544-12-00
5
2026-06-02
Myelodysplastic neoplasms/syndromes (MDS)
-
2025-522007-18-00
5
2026-05-27
Relapsed or Refractory Multiple Myeloma
-
2023-503766-24-00
11
2026-05-26
Moderate to Severe Plaque Psoriasis
-
2024-519930-22-00
4
2026-05-18
Systemic Lupus Erythematosus (SLE) With or Without Active Lupus Nephri
-
2025-523602-33-00
9
2026-05-13
Advanced or unresectable Hepatocellular Carcinoma (HCC)
-
2024-516993-31-00
5
2026-05-11
Renal Cell Carcinoma
-
2023-509628-16-00
5
2026-05-07
Small Cell Lung Cancer (SCLC)
-
2025-523552-31-00
5
2026-05-07
Systemic Lupus Erythematosus
-
2025-523717-29-00
5
2026-04-28
HFpEF or HFmrEF and obesity
-
2025-523804-62-00
5
2026-04-28
Obesity
-
2025-524136-19-00
1
2026-04-28
Selected Advanced or Metastatic Solid Tumors
-
2025-523229-16-00
4
2026-04-27
locally advanced basal cell carcinoma patients
-
2024-520014-22-00
5
2026-04-22
Locally advanced/metastatic urothelial carcinoma
-
2024-519304-28-00
5
2026-04-20
Multiple Sclerosis
-
2025-523803-31-00
4
2026-04-16
Advanced non-small cell lung cancer (NSCLC)
-
2025-523553-34-00
1
2026-04-15
Advanced and Metastatic Solid tumors
-
2025-523085-24-00
5
2026-04-13
Biliary Tract Cancer
-
2025-522403-17-00
5
2026-04-10
Nummular Dermatitis